| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms, Experimental | 12 | 2019 | 269 | 2.160 |
Why?
|
| Immunotherapy | 11 | 2021 | 699 | 1.580 |
Why?
|
| Radiotherapy | 5 | 2020 | 332 | 1.570 |
Why?
|
| Neoplasms | 18 | 2023 | 3067 | 1.380 |
Why?
|
| Dendritic Cells | 16 | 2024 | 451 | 1.280 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2019 | 135 | 1.110 |
Why?
|
| Tumor Escape | 5 | 2017 | 51 | 1.080 |
Why?
|
| Adoptive Transfer | 3 | 2017 | 169 | 1.080 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2015 | 198 | 1.000 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2017 | 600 | 1.000 |
Why?
|
| Myeloid Cells | 2 | 2015 | 101 | 0.900 |
Why?
|
| Interferon-gamma | 8 | 2019 | 449 | 0.860 |
Why?
|
| Genetic Therapy | 8 | 2015 | 372 | 0.820 |
Why?
|
| Radioimmunotherapy | 1 | 2020 | 27 | 0.680 |
Why?
|
| Antibodies, Monoclonal | 9 | 2009 | 1396 | 0.650 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 476 | 0.600 |
Why?
|
| Killer Cells, Natural | 7 | 2012 | 276 | 0.590 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 22 | 0.570 |
Why?
|
| Interleukin-15 | 4 | 2012 | 73 | 0.560 |
Why?
|
| Animals | 43 | 2024 | 27536 | 0.560 |
Why?
|
| Blood Vessels | 1 | 2017 | 94 | 0.560 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 6 | 2009 | 17 | 0.550 |
Why?
|
| T-Lymphocytes | 7 | 2015 | 1221 | 0.540 |
Why?
|
| Cell Line, Tumor | 14 | 2021 | 2588 | 0.540 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 450 | 0.540 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 173 | 0.530 |
Why?
|
| Cell Communication | 2 | 2015 | 200 | 0.520 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2016 | 37 | 0.520 |
Why?
|
| Mice, Inbred C57BL | 19 | 2019 | 3253 | 0.510 |
Why?
|
| B7-H1 Antigen | 2 | 2017 | 279 | 0.500 |
Why?
|
| Mice | 31 | 2024 | 11858 | 0.490 |
Why?
|
| Ischemia | 1 | 2017 | 253 | 0.490 |
Why?
|
| Mice, Knockout | 7 | 2024 | 2016 | 0.440 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 306 | 0.440 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 606 | 0.420 |
Why?
|
| Receptors, Nerve Growth Factor | 4 | 2006 | 12 | 0.420 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2006 | 90 | 0.410 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2013 | 276 | 0.390 |
Why?
|
| Colonic Neoplasms | 5 | 2018 | 572 | 0.380 |
Why?
|
| Membrane Proteins | 5 | 2024 | 1227 | 0.380 |
Why?
|
| Melanoma, Experimental | 3 | 2024 | 111 | 0.370 |
Why?
|
| Interleukin-12 | 5 | 2005 | 111 | 0.360 |
Why?
|
| Macrophages | 1 | 2013 | 582 | 0.350 |
Why?
|
| Liver | 3 | 2012 | 1211 | 0.340 |
Why?
|
| Antigens, Neoplasm | 5 | 2017 | 334 | 0.340 |
Why?
|
| Antigens, CD | 9 | 2008 | 466 | 0.330 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 1704 | 0.320 |
Why?
|
| Plasmacytoma | 1 | 2008 | 34 | 0.320 |
Why?
|
| Tumor Burden | 3 | 2017 | 310 | 0.300 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 169 | 0.290 |
Why?
|
| Interferon Type I | 2 | 2024 | 186 | 0.280 |
Why?
|
| NF-kappa B | 2 | 2021 | 469 | 0.260 |
Why?
|
| Mice, Transgenic | 9 | 2019 | 1579 | 0.260 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2012 | 319 | 0.250 |
Why?
|
| RNA-Binding Proteins | 2 | 2024 | 280 | 0.240 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 334 | 0.230 |
Why?
|
| Isoantigens | 1 | 2004 | 71 | 0.230 |
Why?
|
| Green Fluorescent Proteins | 4 | 2016 | 309 | 0.220 |
Why?
|
| Cell Movement | 3 | 2019 | 787 | 0.220 |
Why?
|
| Immunologic Memory | 3 | 2013 | 164 | 0.220 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2016 | 215 | 0.210 |
Why?
|
| Cancer Vaccines | 3 | 2013 | 159 | 0.210 |
Why?
|
| Lymphocyte Count | 2 | 2017 | 99 | 0.210 |
Why?
|
| Environment | 1 | 2005 | 225 | 0.210 |
Why?
|
| Lymphocyte Activation | 3 | 2016 | 754 | 0.210 |
Why?
|
| Adenoviridae | 6 | 2006 | 349 | 0.210 |
Why?
|
| Spleen | 4 | 2012 | 433 | 0.200 |
Why?
|
| Metal-Organic Frameworks | 1 | 2021 | 15 | 0.190 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1452 | 0.190 |
Why?
|
| Radiation Tolerance | 2 | 2019 | 173 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 326 | 0.190 |
Why?
|
| CDC2 Protein Kinase | 1 | 2021 | 46 | 0.180 |
Why?
|
| Erythroid Precursor Cells | 1 | 2021 | 33 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 7 | 2009 | 1091 | 0.180 |
Why?
|
| CTLA-4 Antigen | 5 | 2008 | 140 | 0.170 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 79 | 0.170 |
Why?
|
| Neutrophils | 1 | 2021 | 311 | 0.170 |
Why?
|
| Humans | 29 | 2024 | 90014 | 0.170 |
Why?
|
| Receptors, Chemokine | 2 | 2013 | 30 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 3 | 2016 | 684 | 0.160 |
Why?
|
| Immunization | 4 | 2013 | 163 | 0.160 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 2395 | 0.160 |
Why?
|
| Transfection | 5 | 2008 | 909 | 0.160 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2018 | 19 | 0.160 |
Why?
|
| Receptors, Interferon | 2 | 2017 | 33 | 0.150 |
Why?
|
| Glioblastoma | 1 | 2021 | 268 | 0.150 |
Why?
|
| Mice, Inbred C3H | 3 | 2013 | 371 | 0.150 |
Why?
|
| Cell Survival | 2 | 2019 | 983 | 0.150 |
Why?
|
| Gene Transfer Techniques | 2 | 2012 | 153 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 204 | 0.150 |
Why?
|
| Flow Cytometry | 6 | 2012 | 690 | 0.150 |
Why?
|
| Immunity, Innate | 2 | 2018 | 434 | 0.140 |
Why?
|
| Antigens, Differentiation | 4 | 2006 | 141 | 0.140 |
Why?
|
| Intravital Microscopy | 1 | 2017 | 11 | 0.140 |
Why?
|
| Necrosis | 1 | 2017 | 210 | 0.140 |
Why?
|
| Antigen Presentation | 4 | 2021 | 215 | 0.130 |
Why?
|
| Substrate Specificity | 1 | 2017 | 352 | 0.130 |
Why?
|
| Stromal Cells | 1 | 2017 | 151 | 0.130 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 166 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2016 | 72 | 0.130 |
Why?
|
| eIF-2 Kinase | 1 | 2015 | 48 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 784 | 0.120 |
Why?
|
| Recombinant Proteins | 4 | 2012 | 1008 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2015 | 57 | 0.120 |
Why?
|
| Nucleotidyltransferases | 1 | 2014 | 31 | 0.120 |
Why?
|
| Wound Healing | 1 | 2017 | 362 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1284 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2018 | 287 | 0.120 |
Why?
|
| Cytokines | 2 | 2017 | 811 | 0.120 |
Why?
|
| Skin Window Technique | 1 | 2013 | 3 | 0.110 |
Why?
|
| Melanoma | 1 | 2018 | 471 | 0.110 |
Why?
|
| Vaccination | 1 | 2016 | 279 | 0.110 |
Why?
|
| Models, Immunological | 2 | 2005 | 81 | 0.110 |
Why?
|
| CD11b Antigen | 1 | 2013 | 36 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2017 | 464 | 0.110 |
Why?
|
| Bacterial Vaccines | 1 | 2013 | 44 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 395 | 0.110 |
Why?
|
| Models, Biological | 2 | 2013 | 1766 | 0.110 |
Why?
|
| Immunity, Cellular | 3 | 2018 | 178 | 0.110 |
Why?
|
| Actins | 1 | 2016 | 462 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 2 | 2003 | 166 | 0.100 |
Why?
|
| DNA | 2 | 2018 | 1311 | 0.100 |
Why?
|
| Lipoproteins, HDL | 1 | 2012 | 97 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 952 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2013 | 173 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2018 | 1670 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 354 | 0.100 |
Why?
|
| CD40 Antigens | 2 | 2008 | 44 | 0.090 |
Why?
|
| Female | 12 | 2024 | 46617 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2016 | 1497 | 0.090 |
Why?
|
| Receptors, Immunologic | 2 | 2007 | 136 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 559 | 0.080 |
Why?
|
| Leukocyte Common Antigens | 1 | 2009 | 48 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2020 | 8292 | 0.080 |
Why?
|
| Cross-Priming | 3 | 2015 | 49 | 0.080 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 1066 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 885 | 0.080 |
Why?
|
| Genes, RAG-1 | 1 | 2008 | 13 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 238 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1243 | 0.070 |
Why?
|
| Parkinsonian Disorders | 1 | 2007 | 21 | 0.070 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 167 | 0.070 |
Why?
|
| Microglia | 1 | 2007 | 108 | 0.070 |
Why?
|
| Radiation, Ionizing | 2 | 2018 | 123 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 262 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2007 | 181 | 0.060 |
Why?
|
| B7-1 Antigen | 1 | 2006 | 76 | 0.060 |
Why?
|
| Transgenes | 1 | 2006 | 185 | 0.060 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2005 | 5 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2005 | 86 | 0.060 |
Why?
|
| Virus Diseases | 1 | 2006 | 99 | 0.060 |
Why?
|
| Immune Tolerance | 2 | 2005 | 341 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2005 | 115 | 0.060 |
Why?
|
| Hepacivirus | 1 | 2005 | 131 | 0.060 |
Why?
|
| Viral Core Proteins | 1 | 2003 | 28 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2004 | 112 | 0.060 |
Why?
|
| Viral Envelope Proteins | 1 | 2003 | 94 | 0.050 |
Why?
|
| Tissue Engineering | 1 | 2004 | 191 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 2 | 2021 | 511 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2002 | 70 | 0.050 |
Why?
|
| Liver Neoplasms | 2 | 2006 | 755 | 0.050 |
Why?
|
| Mastitis, Bovine | 1 | 2001 | 1 | 0.050 |
Why?
|
| Apoptosis | 2 | 2006 | 1718 | 0.050 |
Why?
|
| Macrophage-1 Antigen | 1 | 2001 | 17 | 0.050 |
Why?
|
| Gene Expression | 1 | 2006 | 1309 | 0.050 |
Why?
|
| CD3 Complex | 1 | 2001 | 134 | 0.050 |
Why?
|
| Base Sequence | 2 | 2021 | 2329 | 0.050 |
Why?
|
| Ovalbumin | 2 | 2013 | 109 | 0.050 |
Why?
|
| Mammary Glands, Animal | 1 | 2001 | 80 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 438 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2011 | 1048 | 0.050 |
Why?
|
| Male | 5 | 2018 | 42705 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2021 | 142 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2002 | 114 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1533 | 0.050 |
Why?
|
| Interferon-beta | 2 | 2014 | 126 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 2331 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 980 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2013 | 463 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2018 | 20 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1185 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 50 | 0.040 |
Why?
|
| Binding Sites | 1 | 2021 | 1122 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 59 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 189 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 961 | 0.040 |
Why?
|
| Receptors, Natural Killer Cell | 2 | 2007 | 20 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 374 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 468 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 486 | 0.030 |
Why?
|
| Homeostasis | 1 | 2018 | 418 | 0.030 |
Why?
|
| Chemokines | 1 | 2016 | 74 | 0.030 |
Why?
|
| Bystander Effect | 1 | 2015 | 12 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2018 | 3404 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 2 | 2007 | 284 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 1665 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2887 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2015 | 88 | 0.030 |
Why?
|
| Disease Progression | 2 | 2011 | 1469 | 0.030 |
Why?
|
| Xanthones | 1 | 2014 | 11 | 0.030 |
Why?
|
| Nucleotides, Cyclic | 1 | 2014 | 12 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 246 | 0.030 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2014 | 20 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2014 | 50 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2014 | 49 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1184 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 376 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2006 | 446 | 0.030 |
Why?
|
| Interleukin-15 Receptor alpha Subunit | 1 | 2012 | 6 | 0.030 |
Why?
|
| Epitopes | 1 | 2013 | 254 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 122 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 557 | 0.030 |
Why?
|
| Autoimmunity | 2 | 2006 | 169 | 0.030 |
Why?
|
| Cell Count | 1 | 2012 | 199 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2012 | 70 | 0.030 |
Why?
|
| Inclusion Bodies | 1 | 2012 | 34 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 266 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 793 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 109 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 740 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 143 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 919 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 816 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2007 | 32 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 32 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 1801 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2007 | 66 | 0.020 |
Why?
|
| Mesoderm | 1 | 2007 | 124 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6787 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 323 | 0.020 |
Why?
|
| Time Factors | 2 | 2007 | 5361 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2007 | 197 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2006 | 30 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 2457 | 0.020 |
Why?
|
| Ligands | 1 | 2007 | 447 | 0.020 |
Why?
|
| Dopamine | 1 | 2007 | 276 | 0.020 |
Why?
|
| Viral Vaccines | 1 | 2006 | 44 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2006 | 214 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 19272 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 171 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2006 | 178 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2005 | 73 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2005 | 56 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2004 | 22 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 166 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 206 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2004 | 30 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2006 | 515 | 0.010 |
Why?
|
| Viral Load | 1 | 2005 | 145 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 563 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 145 | 0.010 |
Why?
|
| Fever | 1 | 2004 | 127 | 0.010 |
Why?
|
| Receptors, CCR6 | 1 | 2003 | 3 | 0.010 |
Why?
|
| Chemokine CCL20 | 1 | 2003 | 3 | 0.010 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2003 | 9 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2003 | 69 | 0.010 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2003 | 40 | 0.010 |
Why?
|
| Middle Aged | 2 | 2018 | 26173 | 0.010 |
Why?
|
| Chemokines, CC | 1 | 2003 | 37 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 264 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2003 | 88 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2006 | 995 | 0.010 |
Why?
|
| Adult | 2 | 2018 | 26836 | 0.010 |
Why?
|
| Cell Separation | 1 | 2003 | 199 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2005 | 174 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2003 | 160 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 397 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 741 | 0.010 |
Why?
|
| Cell Death | 1 | 2003 | 261 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 958 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 785 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2002 | 67 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2001 | 46 | 0.010 |
Why?
|
| Abatacept | 1 | 2002 | 86 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2006 | 399 | 0.010 |
Why?
|
| Milk | 1 | 2001 | 53 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2001 | 66 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2001 | 224 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 1158 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 378 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 3024 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 693 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1134 | 0.010 |
Why?
|
| Peptides | 1 | 2003 | 649 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 700 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 4169 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2001 | 278 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 2887 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 2018 | 0.010 |
Why?
|
| Brain | 1 | 2007 | 2306 | 0.010 |
Why?
|